Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 743

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

Lu, Bai, Nagappan, Guhan, Guan, Xiaoming, Nathan, Pradeep J., Wren, Paul·2013·Nature Reviews Neuroscience
DOI 10.1038/nrn3505
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrn3505

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 181

  1. Brookmeyer, R., Johnson, E., Ziegler-Graham, K. & Arrighi, H. M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3, 186–191 (2007). · DOI · Paper page
  2. Dorsey, E. R. et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68, 384–386 (2007). · DOI · Paper page
  3. Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N. & Murtagh, F. R. An English translation of Alzheimer's 1907 paper, “Über eine eigenartige Erkankung der Hirnrinde”. Clin. Anat. 8, 429–431 (1995). · DOI · Paper page
  4. Mullard, A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nature Rev. Drug Discov. 11, 657–660 (2012). · DOI
  5. Herrmann, N., Chau, S. A., Kircanski, I. & Lanctot, K. L. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 71, 2031–2065 (2011). · DOI · Paper page
  6. Perez, S. E. et al. Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. Int. J. Physiol. Pathophysiol. Pharmacol. 4, 115–127 (2012).
  7. Romberg, C., Mattson, M. P., Mughal, M. R., Bussey, T. J. & Saksida, L. M. Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). J. Neurosci. 31, 3500–3507 (2011). · DOI · Paper page
  8. Lemere, C. A. & Masliah, E. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nature Rev. Neurol. 6, 108–119 (2010). · DOI · Paper page
  9. Hellweg, R., Wirth, Y., Janetzky, W. & Hartmann, S. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. Int. J. Geriatr. Psychiatry 27, 651–656 (2011). · DOI
  10. Rodda, J., Morgan, S. & Walker, Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int. Psychogeriatr. 21, 813–824 (2009). · DOI · Paper page
  11. Lewis, D. A. & Sweet, R. A. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J. Clin. Invest. 119, 706–716 (2009). In this review, the authors emphasize the importance of separating pathogenesis from pathophysiology and suggest that therapeutic interventions for complex diseases such as schizophrenia might be more effective by focusing on pathophysiology, which is closer to clinical features. · DOI · Paper page
  12. Villemagne, V. L. et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357–367 (2013). A study that provides an estimate of changes in rates of Aβ deposition, cerebral atrophy and cognitive decline in healthy subjects, patients with MCI and patients with AD. Projections based on this longitudinal measurement suggest a protracted (∼17 years) preclinical phase of AD. · DOI · Paper page
  13. Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572–580 (1991). · DOI · Paper page
  14. Shankar, G. M. & Walsh, D. M. Alzheimer's disease: synaptic dysfunction and Aβ. Mol. Neurodegener. 4, 48 (2009). · DOI · Paper page
  15. Marchetti, C. & Marie, H. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? Rev. Neurosci. 22, 373–402 (2011). · DOI
  16. Hsiao, K. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99–102 (1996). · DOI · Paper page
  17. Dong, H., Martin, M. V., Chambers, S. & Csernansky, J. G. Spatial relationship between synapse loss and β-amyloid deposition in Tg2576 mice. J. Comp. Neurol. 500, 311–321 (2007). · DOI
  18. Davies, C. A., Mann, D. M., Sumpter, P. Q. & Yates, P. O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 78, 151–164 (1987). · DOI · Paper page
  19. Masliah, E., Mallory, M., Hansen, L., DeTeresa, R. & Terry, R. D. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 43, 192–197 (1993). · DOI · Paper page
  20. Scheff, S. W., Price, D. A., Schmitt, F. A., DeKosky, S. T. & Mufson, E. J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501–1508 (2007). · DOI · Paper page
  21. Chen, K. et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 56, 52–60 (2011). · DOI · Paper page
  22. Milnerwood, A. J. & Raymond, L. A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 33, 513–523 (2010). · DOI · Paper page
  23. Picconi, B., Piccoli, G. & Calabresi, P. Synaptic dysfunction in Parkinson's disease. Adv. Exp. Med. Biol. 970, 553–572 (2012). · DOI · Paper page
  24. Bagetta, V., Ghiglieri, V., Sgobio, C., Calabresi, P. & Picconi, B. Synaptic dysfunction in Parkinson's disease. Biochem. Soc. Trans. 38, 493–497 (2010). · DOI · Paper page
  25. Galvin, J. E., Uryu, K., Lee, V. M. & Trojanowski, J. Q. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein. Proc. Natl Acad. Sci. USA 96, 13450–13455 (1999). · DOI · Paper page
  26. DiProspero, N. A. et al. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol. 33, 517–533 (2004). · DOI
  27. Mayford, M., Siegelbaum, S. A. & Kandel, E. R. Synapses and memory storage. Cold Spring Harb. Perspect. Biol. 4, a005751 (2012). · DOI · Paper page
  28. Maletic-Savatic, M., Malinow, R. & Svoboda, K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science 283, 1923–1927 (1999). · DOI · Paper page
  29. Engert, F. & Bonhoeffer, T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399, 66–70 (1999). · DOI · Paper page
  30. Cheeran, B. et al. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J. Physiol. 586, 5717–5725 (2008). · DOI · Paper page
  31. Fritsch, B. et al. Direct current stimulation promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. Neuron 66, 198–204 (2010). This paper demonstrates the use of a non-invasive approach — transcranial direct current stimulation — to alter BDNF secretion in human brain in vivo , suggesting that this approach improves motor learning by inducing LTP that is dependent on BDNF secretion in the motor cortex. · DOI · Paper page
  32. Ferrer, I., Goutan, E., Marin, C., Rey, M. J. & Ribalta, T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 866, 257–261 (2000). · DOI · Paper page
  33. Zuccato, C. et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493–498 (2001). · DOI · Paper page
  34. Durany, N. et al. Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int. J. Dev. Neurosci. 18, 807–813 (2000). · DOI
  35. Phillips, H. S. et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7, 695–702 (1991). · DOI · Paper page
  36. Frerking, M., Malenka, R. C. & Nicoll, R. A. Brain-derived neurotrophic factor (BDNF) modulates inhibitory, but not excitatory, transmission in the CA1 region of the hippocampus. J. Neurophysiol. 80, 3383–3386 (1998). · DOI · Paper page
  37. Gottschalk, W., Pozzo-Miller, L. D., Figurov, A. & Lu, B. Presynaptic modulation of synaptic transmission and plasticity by brain-derived neurotrophic factor in the developing hippocampus. J. Neurosci. 18, 6830–6839 (1998). · DOI · Paper page
  38. Akaneya, Y., Tsumoto, T., Kinoshita, S. & Hatanaka, H. Brain-derived neurotrophic factor enhances long-term potentiation in rat visual cortex. J. Neurosci. 17, 6707–6716 (1997). · DOI · Paper page
  39. Huber, K. M., Sawtell, N. B. & Bear, M. F. Brain-derived neurotrophic factor alters the synaptic modification threshold in visual cortex. Neuropharmacology 37, 571–579 (1998). · DOI
  40. Korte, M. et al. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl Acad. Sci. USA 92, 8856–8860 (1995). · DOI · Paper page
  41. Minichiello, L. et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 24, 401–414 (1999). · DOI · Paper page
  42. Xu, B. et al. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J. Neurosci. 20, 6888–6897 (2000). · DOI · Paper page
  43. Ji, Y. et al. Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nature Neurosci. 13, 302–309 (2010). This study resolves a long-term dispute: whether BDNF enhances basal synaptic transmission. It demonstrates that a gradual increase in BDNF concentration facilitates LTP, whereas a rapid rise of BDNF concentration increases basal synaptic transmission. Thus, a single extracellular factor could induce distinct signalling and functions based on how it is delivered. · DOI · Paper page
  44. Lu, Y., Christian, K. & Lu, B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol. Learn. Mem. 89, 312–323 (2008). · DOI · Paper page
  45. Korte, M., Kang, H., Bonhoeffer, T. & Schuman, E. A role for BDNF in the late-phase of hippocampal long-term potentiation. Neuropharmacology 37, 553–559 (1998). · DOI · Paper page
  46. Balkowiec, A. & Katz, D. M. Activity-dependent release of endogenous brain-derived neurotrophic factor from primary sensory neurons detected by ELISA in situ. J. Neurosci. 20, 7417–7423 (2000). · DOI · Paper page
  47. Balkowiec, A. & Katz, D. M. Cellular mechanisms regulating activity-dependent release of native brain-derived neurotrophic factor from hippocampal neurons. J. Neurosci. 22, 10399–10407 (2002). · DOI · Paper page
  48. Nagappan, G. et al. Control of extracellular cleavage of ProBDNF by high frequency neuronal activity. Proc. Natl Acad. Sci. USA 106, 1267–1272 (2009). · DOI · Paper page
  49. Patterson, S. L., Grover, L. M., Schwartzkroin, P. A. & Bothwell, M. Neurotrophin expression in rat hippocampal slices: a stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs. Neuron 9, 1081–1088 (1992). · DOI · Paper page
  50. Chen, G., Kolbeck, R., Barde, Y. A., Bonhoeffer, T. & Kossel, A. Relative contribution of endogenous neurotrophins in hippocampal long-term potentiation. J. Neurosci. 19, 7983–7990 (1999). · DOI · Paper page
  51. Pang, P. T. et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306, 487–491 (2004). · DOI · Paper page
  52. Barco, A. et al. Gene expression profiling of facilitated L-LTP in VP16-CREB mice reveals that BDNF is critical for the maintenance of LTP and its synaptic capture. Neuron 48, 123–137 (2005). · DOI · Paper page
  53. Lu, Y. et al. TrkB as a potential synaptic and behavioral tag. J. Neurosci. 31, 11762–11771 (2011). · DOI
  54. McAllister, A. K., Lo, D. C. & Katz, L. C. Neurotrophins regulate dendritic growth in developing visual cortex. Neuron 15, 791–803 (1995). · DOI · Paper page
  55. Cabelli, R. J., Hohn, A. & Shatz, C. J. Inhibition of ocular dominance column formation by infusion of NT-4/5 or BDNF. Science 267, 1662–1666 (1995). · DOI · Paper page
  56. Tyler, W. J. & Pozzo-Miller, L. Miniature synaptic transmission and BDNF modulate dendritic spine growth and form in rat CA1 neurones. J. Physiol. 553, 497–509 (2003). An important study that clearly demonstrates the pharmacological effect of BDNF on synaptic growth; that is, it found an increase in the number of dendritic spines. · DOI · Paper page
  57. Tartaglia, N. et al. Protein synthesis-dependent and -independent regulation of hippocampal synapses by brain-derived neurotrophic factor. J. Biol. Chem. 276, 37585–37593 (2001). · DOI · Paper page
  58. Horch, H. W., Kruttgen, A., Portbury, S. D. & Katz, L. C. Destabilization of cortical dendrites and spines by BDNF. Neuron 23, 353–364 (1999). · DOI · Paper page
  59. Pozzo-Miller, L. D. et al. Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. J. Neurosci. 19, 4972–4983 (1999). · DOI · Paper page
  60. Otal, R., Martinez, A. & Soriano, E. Lack of TrkB and TrkC signaling alters the synaptogenesis and maturation of mossy fiber terminals in the hippocampus. Cell Tissue Res. 319, 349–358 (2005). · DOI
  61. Aguado, F. et al. BDNF regulates spontaneous correlated activity at early developmental stages by increasing synaptogenesis and expression of the K+/Cl− co-transporter KCC2. Development 130, 1267–1280 (2003). · DOI · Paper page
  62. Singh, B. et al. Altered balance of glutamatergic/GABAergic synaptic input and associated changes in dendrite morphology after BDNF expression in BDNF-deficient hippocampal neurons. J. Neurosci. 26, 7189–7200 (2006). · DOI
  63. Ma, Y. L., Wang, H. L., Wu, H. C., Wei, C. L. & Lee, E. H. Brain-derived neurotrophic factor antisense oligonucleotide impairs memory retention and inhibits long-term potentiation in rats. Neuroscience 82, 957–967 (1998).
  64. Mu, J. S., Li, W. P., Yao, Z. B. & Zhou, X. F. Deprivation of endogenous brain-derived neurotrophic factor results in impairment of spatial learning and memory in adult rats. Brain Res. 835, 259–265 (1999). · DOI · Paper page
  65. Chen, X. et al. A chemical-genetic approach to studying neurotrophin signaling. Neuron 46, 13–21 (2005). · DOI · Paper page
  66. Johnson, A. W. et al. The brain-derived neurotrophic factor receptor TrkB is critical for the acquisition but not expression of conditioned incentive value. Eur. J. Neurosci. 28, 997–1002 (2008). · DOI
  67. Alonso, M., Vianna, M. R., Izquierdo, I. & Medina, J. H. Signaling mechanisms mediating BDNF modulation of memory formation in vivo in the hippocampus. Cell. Mol. Neurobiol. 22, 663–674 (2002). · DOI
  68. Soliman, F. et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 327, 863–866 (2010). · DOI · Paper page
  69. Martinowich, K. & Lu, B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33, 73–83 (2008). · DOI · Paper page
  70. Martinowich, K., Manji, H. & Lu, B. New insights into BDNF function in depression and anxiety. Nature Neurosci. 10, 1089–1093 (2007). · DOI · Paper page
  71. Rakofsky, J. J., Ressler, K. J. & Dunlop, B. W. BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity. Mol. Psychiatry 17, 22–35 (2012). · DOI
  72. Kemppainen, S. et al. Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol. Aging 33, 1122.e23–1122.e39 (2012). · DOI
  73. Zeng, Y., Zhao, D. & Xie, C. W. Neurotrophins enhance CaMKII activity and rescue amyloid-β-induced deficits in hippocampal synaptic plasticity. J. Alzheimers Dis. 21, 823–831 (2010). · DOI
  74. Chen, Z. Y. et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314, 140–143 (2006). · DOI · Paper page
  75. Szeszko, P. R. et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol. Psychiatry 10, 631–636 (2005). · DOI · Paper page
  76. Yang, X. et al. Impact of brain-derived neurotrophic factor Val66Met polymorphism on cortical thickness and voxel-based morphometry in healthy Chinese young adults. PLoS ONE 7, e37777 (2012). · DOI
  77. Molendijk, M. L. et al. A systematic review and meta-analysis on the association between BDNF val66met and hippocampal volume — a genuine effect or a winners curse? Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 731–740 (2012). · DOI
  78. Campbell, S., Marriott, M., Nahmias, C. & MacQueen, G. M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am. J. Psychiatry 161, 598–607 (2004). · DOI · Paper page
  79. Zivadinov, R. et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum. Mol. Genet. 16, 2659–2668 (2007). · DOI
  80. Voineskos, A. N. et al. The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. Arch. Gen. Psychiatry 68, 198–206 (2011). · DOI
  81. Dennis, N. A. et al. Brain-derived neurotrophic factor val66met polymorphism and hippocampal activation during episodic encoding and retrieval tasks. Hippocampus 21, 980–989 (2011). · DOI
  82. Putcha, D. et al. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J. Neurosci. 31, 17680–17688 (2011). · DOI · Paper page
  83. Yassa, M. A. et al. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment. Neuroimage 51, 1242–1252 (2010). · DOI · Paper page
  84. Dempster, E. et al. Association between BDNF val66 met genotype and episodic memory. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134B, 73–75 (2005). · DOI · Paper page
  85. Ho, B. C. et al. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch. Gen. Psychiatry 63, 731–740 (2006). · DOI · Paper page
  86. Miyajima, F. et al. Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. Genes Brain Behav. 7, 411–417 (2008). · DOI · Paper page
  87. Schofield, P. R. et al. Disturbances in selective information processing associated with the BDNF Val66Met polymorphism: evidence from cognition, the P300 and fronto-hippocampal systems. Biol. Psychol. 80, 176–188 (2009). · DOI
  88. Mandelman, S. D. & Grigorenko, E. L. BDNF Val66Met and cognition: all, none, or some? A meta-analysis of the genetic association. Genes Brain Behav. 11, 127–136 (2012). · DOI · Paper page
  89. Cirillo, J., Hughes, J., Ridding, M., Thomas, P. Q. & Semmler, J. G. Differential modulation of motor cortex excitability in BDNF Met allele carriers following experimentally induced and use-dependent plasticity. Eur. J. Neurosci. 36, 2640–2649 (2012). · DOI
  90. Antal, A. et al. Brain-derived neurotrophic factor (BDNF) gene polymorphisms shape cortical plasticity in humans. Brain Stimul. 3, 230–237 (2010). · DOI · Paper page
  91. Witte, A. V. et al. Interaction of BDNF and COMT polymorphisms on paired-associative stimulation-induced cortical plasticity. J. Neurosci. 32, 4553–4561 (2012). · DOI
  92. Li Voti, P. et al. Correlation between cortical plasticity, motor learning and BDNF genotype in healthy subjects. Exp. Brain Res. 212, 91–99 (2011). · DOI
  93. Di Lazzaro, V. et al. The effects of prolonged cathodal direct current stimulation on the excitatory and inhibitory circuits of the ipsilateral and contralateral motor cortex. J. Neural Transm. 119, 1499–1506 (2012). · DOI
  94. Gatt, J. M. et al. Association between BDNF Val66Met polymorphism and trait depression is mediated via resting EEG alpha band activity. Biol. Psychol. 79, 275–284 (2008). · DOI
  95. Beste, C. et al. The role of the BDNF Val66Met polymorphism for the synchronization of error-specific neural networks. J. Neurosci. 30, 10727–10733 (2010). · DOI
  96. Bian, J. T., Zhang, J. W., Zhang, Z. X. & Zhao, H. L. Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer's disease (AD) in mainland Chinese. Neurosci. Lett. 387, 11–16 (2005). · DOI
  97. Borroni, B. et al. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol. Aging 30, 1406–1412 (2009). · DOI
  98. Lim, Y. Y. et al. Modulation of Aβ amyloid-related cognitive decline by brain-derived neurotrophic factor Val66Met polymorphism in preclinical Alzheimer's disease. Neurobiol. Aging (in the press). A longitudinal study demonstrating an epistatic relationship between the BDNF Val66Met polymorphism and amyloid deposition in both preclinical and clinical phases of AD. Subjects with high levels of Aβ combined with the BDNFMet polymorphism showed a faster decline in hippocampal volume and episodic memory.
  99. Karamohamed, S. et al. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology 65, 1823–1825 (2005). · DOI
  100. Momose, Y. et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 51, 133–136 (2002). · DOI · Paper page
  101. Parsian, A., Sinha, R., Racette, B., Zhao, J. H. & Perlmutter, J. S. Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease. Parkinsonism Relat. Disord. 10, 213–219 (2004). · DOI
  102. Guerini, F. R. et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur. J. Neurol. 16, 1240–1245 (2009). · DOI
  103. Liu, J. et al. Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Parkinsonism Relat. Disord. 18, 140–143 (2012). · DOI
  104. Ninan, I. et al. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J. Neurosci. 30, 8866–8870 (2010). · DOI · Paper page
  105. Liu, R. J. et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 71, 996–1005 (2012). · DOI · Paper page
  106. Cao, L. et al. Genetic modulation of BDNF signaling affects the outcome of axonal competition in vivo. Curr. Biol. 17, 911–921 (2007). · DOI
  107. Bradley, W. G. Miami, F. L. & the BDNF Trial Group. A PhaseI/II study of recombinant human brain-derived neurotrophic factor in patients with amyotrophic lateral sclerosis. Ann. Neurol. 38, 971 (1995). · DOI
  108. [No authors listed.] A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52, 1427–1433 (1999). · DOI · Paper page
  109. Apfel, S. C. Is the therapeutic application of neurotrophic factors dead? Ann. Neurol. 51, 8–11 (2002). · DOI
  110. Henriques, A., Pitzer, C. & Schneider, A. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front. Neurosci. 4, 32 (2010).
  111. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419–424 (2012). · DOI · Paper page
  112. Dittrich, F. et al. Pharmacokinetics of intrathecally applied BDNF and effects on spinal motoneurons. Exp. Neurol. 141, 225–239 (1996). · DOI
  113. Lampe, K. J., Kern, D. S., Mahoney, M. J. & Bjugstad, K. B. The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: protein distribution and the glial response. J. Biomed. Mater. Res. A 96, 595–607 (2011). · DOI
  114. Bertram, J. P., Rauch, M. F., Chang, K. & Lavik, E. B. Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: delivery of BDNF. Pharm. Res. 27, 82–91 (2010). · DOI
  115. Boado, R. J., Zhang, Y. & Pardridge, W. M. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood–brain barrier. Biotechnol. Bioeng. 97, 1376–1386 (2007). · DOI
  116. Zhang, Y. & Pardridge, W. M. Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 889, 49–56 (2001). · DOI · Paper page
  117. Demeule, M. et al. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324, 1064–1072 (2008). · DOI · Paper page
  118. Gaillard, P. J., Visser, C. C. & de Boer, A. G. Targeted delivery across the blood–brain barrier. Expert Opin. Drug Deliv. 2, 299–309 (2005). · DOI
  119. Muruganandam, A., Tanha, J., Narang, S. & Stanimirovic, D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood–brain barrier endothelium. FASEB J. 16, 240–242 (2002). · DOI · Paper page
  120. Geral, C., Angelova, A. & Lesieur, S. From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF). Pharmaceutics 5, 127–167 (2013). A comprehensive review describing the approaches to deliver BDNF and other proteins into the CNS using nanotechnology. · DOI
  121. Gabathuler, R. Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48–57 (2010). · DOI · Paper page
  122. Alcala-Barraza, S. R. et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J. Drug Target 18, 179–190 (2010). · DOI · Paper page
  123. Jiang, Y. et al. Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 172, 398–405 (2011). · DOI · Paper page
  124. Poduslo, J. F. & Curran, G. L. Permeability at the blood–brain and blood–nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res. Mol. Brain Res. 36, 280–286 (1996). · DOI · Paper page
  125. Sakane, T. & Pardridge, W. M. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm. Res. 14, 1085–1091 (1997). · DOI
  126. Jang, S. W. et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl Acad. Sci. USA 107, 2687–2692 (2010). · DOI · Paper page
  127. Lin, J. C. et al. Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates. PLoS ONE 3, e1900 (2008). · DOI
  128. O'Leary, P. D. & Hughes, R. A. Design of potent peptide mimetics of brain-derived neurotrophic factor. J. Biol. Chem. 278, 25738–25744 (2003). · doi:10.1074/jbc.m212208200
  129. Fletcher, J. M. & Hughes, R. A. Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor. J. Pept. Sci. 12, 515–524 (2006). · DOI
  130. Jang, S. W. et al. Deoxygedunin, a natural product with potent neurotrophic activity in mice. PLoS ONE 5, e11528 (2010). · DOI · Paper page
  131. Tsao, D. et al. TrkB agonists ameliorate obesity and associated metabolic conditions in mice. Endocrinology 149, 1038–1048 (2008). · DOI
  132. Xu, L., Zhang, Y., Cohen, S. B. & DiPetrillo, K. TrkB agonist antibody dose-dependently raises blood pressure in mice with diet-induced obesity. Am. J. Hypertens. 23, 732–736 (2010). · DOI
  133. Zoladz, J. A. & Pilc, A. The effect of physical activity on the brain derived neurotrophic factor: from animal to human studies. J. Physiol. Pharmacol. 61, 533–541 (2010).
  134. Knaepen, K., Goekint, M., Heyman, E. M. & Meeusen, R. Neuroplasticity — exercise-induced response of peripheral brain-derived neurotrophic factor: a systematic review of experimental studies in human subjects. Sports Med. 40, 765–801 (2010). · DOI · Paper page
  135. Saarelainen, T. et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23, 349–357 (2003). · DOI · Paper page
  136. Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959–964 (2010). · DOI · Paper page
  137. Marvanova, M. et al. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol. Cell Neurosci. 18, 247–258 (2001). · DOI
  138. Leyhe, T., Stransky, E., Eschweiler, G. W., Buchkremer, G. & Laske, C. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 258, 124–128 (2008). · DOI
  139. Autio, H. et al. Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus. Neuropharmacology 61, 1291–1296. · DOI
  140. Hashimoto, R. et al. Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease. Genes Brain Behav. 8, 43–52 (2009). · DOI
  141. Adamczuk, K. et al. Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein Eɛ4 carriers. Neuroimage Clin. (in the press).
  142. Blin, O., Davies, C. H. & Lu, B. Clinical innovation for neurodegenerative diseases. Clin. Invest. 2, 663–665 (2012). · doi:10.4155/cli.12.65
  143. Huang, Y. & Morozov, A. Hippocampal deletion of BDNF gene attenuates gamma oscillations in area CA1 by up-regulating 5-HT3 receptor. PLoS ONE 6, e16480 (2011). · DOI
  144. Zheng, K. et al. TrkB signaling in parvalbumin-positive interneurons is critical for gamma-band network synchronization in hippocampus. Proc. Natl Acad. Sci. USA 108, 17201–17206 (2011). · DOI
  145. Rossini, P. M. et al. Conversion from mild cognitive impairment to Alzheimer's disease is predicted by sources and coherence of brain electroencephalography rhythms. Neuroscience 143, 793–803 (2006). · DOI · Paper page
  146. Lai, C. L., Lin, R. T., Liou, L. M. & Liu, C. K. The role of event-related potentials in cognitive decline in Alzheimer's disease. Clin. Neurophysiol. 121, 194–199 (2010). · DOI
  147. Miller, G. Alzheimer's research. Stopping Alzheimer's before it starts. Science 337, 790–792 (2012). · DOI · Paper page
  148. Alonso Canovas, A. et al. Dopaminergic agonists in Parkinson's disease. Neurologia 2 Jul 2011 (doi:10.1016/j.nrl.2011.04.012). · DOI
  149. Tong, L. & Perez-Polo, R. Brain-derived neurotrophic factor (BDNF) protects cultured rat cerebellar granule neurons against glucose deprivation-induced apoptosis. J. Neural Transm. 105, 905–914 (1998). · DOI
  150. Ferenz, K. B. et al. Nerve growth factor and brain-derived neurotrophic factor but not granulocyte colony-stimulating factor, nimodipine and dizocilpine, require ATP for neuroprotective activity after oxygen-glucose deprivation of primary neurons. Brain Res. 1448, 20–26 (2012). · DOI
  151. Lee, B. et al. The CREB/CRE transcriptional pathway: protection against oxidative stress-mediated neuronal cell death. J. Neurochem. 108, 1251–1265 (2009). · DOI · Paper page
  152. Lindholm, D., Dechant, G., Heisenberg, C. P. & Thoenen, H. Brain-derived neurotrophic factor is a survival factor for cultured rat cerebellar granule neurons and protects them against glutamate-induced neurotoxicity. Eur. J. Neurosci. 5, 1455–1464 (1993). · DOI · Paper page
  153. Arancibia, S. et al. Protective effect of BDNF against β-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol. Dis. 31, 316–326 (2008). · DOI · Paper page
  154. Müller, H. D. et al. Brain-derived neurotrophic factor but not forced arm use improves long-term outcome after photothrombotic stroke and transiently upregulates binding densities of excitatory glutamate receptors in the rat brain. Stroke 39, 1012–1021 (2008). · DOI
  155. Shults, C. W., Kimber, T. & Altar, C. A. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. Neuroreport 6, 1109–1112 (1995). · DOI
  156. Tandon, P., Yang, Y., Das, K., Holmes, G. L. & Stafstrom, C. E. Neuroprotective effects of brain-derived neurotrophic factor in seizures during development. Neuroscience 91, 293–303 (1999). · DOI
  157. Luikart, B. W. et al. TrkB has a cell-autonomous role in the establishment of hippocampal Schaffer collateral synapses. J. Neurosci. 25, 3774–3786 (2005). · DOI · Paper page
  158. Cattaneo, A., Capsoni, S. & Paoletti, F. Towards non invasive nerve growth factor therapies for Alzheimer's disease. J. Alzheimers Dis. 15, 255–283 (2008). · DOI
  159. Shimizu, E., Hashimoto, K. & Iyo, M. Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: the possibility to explain ethnic mental traits. Am. J. Med. Genet. B Neuropsychiatr. Genet. 126B, 122–123 (2004). · DOI · Paper page
  160. Ramasamy, D. P. et al. Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: a voxel-based morphometry study. Pathophysiology 18, 53–60 (2011). · DOI
  161. Hall, D., Dhilla, A., Charalambous, A., Gogos, J. A. & Karayiorgou, M. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am. J. Hum. Genet. 73, 370–376 (2003). · DOI · Paper page
  162. Geller, B. et al. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am. J. Psychiatry 161, 1698–1700 (2004). · DOI · Paper page
  163. Martinez, A. et al. TrkB and TrkC signaling are required for maturation and synaptogenesis of hippocampal connections. J. Neurosci. 18, 7336–7350 (1998). · DOI · Paper page
  164. Jang, S. W. et al. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc. Natl Acad. Sci. USA 107, 3876–3881 (2010). · DOI · Paper page
  165. Lee, F. S. & Chao, M. V. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl Acad. Sci. USA 98, 3555–3560 (2001). · DOI · Paper page
  166. Lee, F. S., Rajagopal, R., Kim, A. H., Chang, P. C. & Chao, M. V. Activation of Trk neurotrophin receptor signaling by pituitary adenylate cyclase-activating polypeptides. J. Biol. Chem. 277, 9096–9102 (2002). · DOI · Paper page
  167. Swift, J. L. et al. Quantification of receptor tyrosine kinase transactivation through direct dimerization and surface density measurements in single cells. Proc. Natl Acad. Sci. USA 108, 7016–7021 (2011). · DOI
  168. Huang, Y. Z., Pan, E., Xiong, Z. Q. & McNamara, J. O. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber–CA3 pyramid synapse. Neuron 57, 546–558 (2008). · DOI · Paper page
  169. Fletcher, J. M. et al. Design of a conformationally defined and proteolytically stable circular mimetic of brain-derived neurotrophic factor. J. Biol. Chem. 283, 33375–33383 (2008). · DOI
  170. Peter, J.-C. et al. Anti-trkb antibodies as pharmacological tools to study the function of the TrkB receptor and its role in the regulation of food intake. Pharmacologia 4, 1–14 (2013). · DOI
  171. Huang, Y. Z. et al. RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol. Pharmacol. 82, 623–635 (2012). · DOI
  172. Lauterborn, J. C., Lynch, G., Vanderklish, P., Arai, A. & Gall, C. M. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J. Neurosci. 20, 8–21 (2000). · DOI · Paper page
  173. Lauterborn, J. C. et al. Chronic elevation of brain-derived neurotrophic factor by ampakines. J. Pharmacol. Exp. Ther. 307, 297–305 (2003). · DOI
  174. Lauterborn, J. C. et al. Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression. Neuroscience 159, 283–295 (2009). · DOI
  175. Legutko, B., Li, X. & Skolnick, P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 40, 1019–1027 (2001). · DOI
  176. Nibuya, M., Nestler, E. J. & Duman, R. S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 16, 2365–2372 (1996). · DOI · Paper page
  177. Deogracias, R. et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc. Natl Acad. Sci. USA 109, 14230–14235 (2012). · DOI · Paper page
  178. Apostol, B. L. et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol. Cell Neurosci. 39, 8–20 (2008). · DOI
  179. Kotani, S., Yamauchi, T., Teramoto, T. & Ogura, H. Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. Neuroscience 142, 505–514 (2006). · DOI · Paper page
  180. Wang, Z. F., Tang, L. L., Yan, H., Wang, Y. J. & Tang, X. C. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol. Biochem. Behav. 83, 603–611 (2006). · DOI
  181. Borrell-Pages, M. et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116, 1410–1424 (2006). · DOI · Paper page

Cited by

See all 743

Metadata

Authors
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P.
Venue
Nature Reviews Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2013-05-15
Volume
14
Issue
6
Pages
401-416
ISSN
  • 1471-003X (ISSN-L)
  • 1471-0048
DOI
10.1038/nrn3505
OpenAlex
W1974476511
Cited by
743
References
57
FWCI
4.30
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. https://app.cochat.ai/papers/10.1038/nrn3505
The paper
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013). BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature Reviews Neuroscience. https://doi.org/10.1038/nrn3505

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.